Anixa Biosciences Inc (ANIX) 10-Q Quarterly Report Tue Sep 08 2020

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jul. 31, 2020	Sep. 08, 2020
Cover [Abstract]
Entity Registrant Name	Anixa Biosciences Inc
Entity Central Index Key	0000715446
Document Type	10-Q
Document Period End Date	Jul. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		23,789,386
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/715446/000149315220017421/form10-q.htm

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Financial

Revenue

Other

Filter by Subcategory:

All

Expense

Product

Cash Flow

Income

Other

Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Financial - Expense Highlight
Research and Development Expenses Research and development expenses are related to the development of our cancer diagnostics and therapeutics programs and our anti-viral drug program, and decreased by approximately $628,000 to approximately $3,974,000 in the nine months ended July 31, 2020, from approximately $4,602,000 in the nine months ended July 31, 2019.

Revenue - Product Highlight
Accordingly, the performance obligations from this license agreement were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
Revenue - Product Highlight
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $91,000 to approximately $57,000 in the nine months ended July 31, 2020, from approximately $148,000 in the nine months ended July 31, 2019, as Certainty's net loss decreased.
Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $11,000 to approximately $15,000 in the three months ended July 31, 2020, from approximately $26,000 in the three months ended July 31, 2019, as Certainty's net loss decreased.
Revenue - Product
Cash provided by financing activities...Read more
Financial - Expense
The decrease in Certainty's net...Read more
Financial - Expense
The decrease in Certainty's net...Read more
Financial - Cash Flow
We can give no assurance...Read more
Other - Other
As a result, our cash,...Read more
Financial - Expense
The decrease in research and...Read more
Financial - Expense
General and Administrative Expenses General...Read more
Financial - Cash Flow
25 The impairment in carrying...Read more
Financial - Expense
General and Administrative Expenses General...Read more
Financial - Income
Interest income decreased by approximately...Read more
Financial - Income
Interest income decreased by approximately...Read more
Financial - Expense
The increase in research and...Read more
Financial - Expense
Patent assertion expenses decreased from...Read more
Revenue - Product
We believe that, of the...Read more
Financial - Expense
The increase in general and...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-20-017421
Submitted to the SEC: Tue Sep 08 2020 4:30:33 PM EST
Accepted by the SEC: Tue Sep 08 2020
Period: Friday, July 31, 2020
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001493152-20-017421.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly report for the period ending Friday, July 31, 2020

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News